Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
You may also be interested in...
The company, which makes generic opioid products and the controversial Acthar Gel, is looking to chart a new course for the future – or make that two new courses.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
With relatively few new drugs in development for opioid-induced constipation, the category is wide open for new entrants to conduct clinical studies and make a difference for patients; a Market Spotlight report from Datamonitor Healthcare reviews the indication's outlook.